|
Outcomes measured in a randomized controlled trial of recombinant activated factor VII |
||||||
| Blunt trauma |
Penetrating trauma |
|||||
|
|
|
|||||
| Outcomes |
rFVIIa |
Placebo |
P |
rFVIIa |
Placebo |
P |
|
|
||||||
| Mortality |
25% |
30% |
0.58 |
24% |
28% |
0.69 |
| MOF/ARDS |
10% |
23% |
0.07 |
7% |
17% |
0.11 |
| ICU-free days |
13 |
8 |
0.18 |
24 |
20 |
0.26 |
| Ventilation-free days |
17 |
14 |
0.44 |
26 |
22 |
0.17 |
|
Both intensive care unit (ICU)-free and ventilator-free days were measured for 30 days. ARDS, acute respiratory distress syndrome; MOF, multiple organ failure; rFVIIa, activated recombinant factor VII. | ||||||
Mohr et al. Critical Care 2005 9(Suppl 5):S37 doi:10.1186/cc3784 |
||||||